Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "novel ankyrin repeat domain 20 family member pseudogene" (ENSG00000288694) is annotated as a human pseudogene and is not believed to produce a functional protein product. While its designation refers to homology with the ankyrin repeat domain 20 family, this locus is non-coding and does not participate in known biological or pathological processes. It is not considered a therapeutic target in drug discovery or pharmacology, and no genetic or functional associations relevant to human disease, biomarkers, drug action, or safety have been described in the literature or curated databases as of the present date. This "target" is a pseudogene: an inactive genomic locus resembling a member of the ankyrin repeat domain family, with no evidence for a role as a functional protein or drug target. Using this as a candidate for therapeutic targeting, biomarker development, or mechanism studies is unsupported by the current evidence.
None applicable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel ankyrin repeat domain 20 family member pseudogene (ENSG00000288694).